|Articles|December 8, 2014
Sandoz's Biosimilar Shows Similarity to Amgen's Neupogen
Author(s)Agnes Shanley
Sandoz announces their version of filgrastim, a follow-on biologic for the treatment of neutropenia, is as safe and effective as Amgen's Neupogen.
Advertisement
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Chiesi–Aliada Partnership Advances BBB-Crossing Technology for Lysosomal Storage Disorders
2
Why Biopharma Developers Should Care About FDA’s New Personalized Therapy Approval Process
3
How Advanced PK/TK Protocols Strengthen Data Integrity
4
BioPharm Weekly News Roundup—Week of Nov. 10, 2025
5
